Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02150525 · ClinicalTrials.gov registry record · Phase 2
Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors
A Phase 2 study of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT02150525: Completed Phase 2 study of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Ohio State University Comprehensive Cancer Center.
NCT02150525 is a Phase 2 study of Breast Cancer Stage II and Breast Cancer Stage III that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 52 participants, below the 180-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02150525, a Phase 2 study of Breast Cancer Stage II and Breast Cancer Stage III, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized double-blind clinical trial studied the effect of oral omega-3 fatty acid on atrophic vaginitis in postmenopausal breast cancer survivors (N=52). Omega-3 fatty acid may reduce inflammation and improve vaginal symptoms in postmenopausal breast cancer survivors.
Primary Outcome
Self-reported measures included the Urogenital Atrophy Questionnaire, Brief Pain Inventory, Menopause Rating Scale, and Female Sexual Function Index. These measures were compared in women assigned to omega 3 fatty acids vs. women assigned to placebo of dietary supplement.
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT omega-3 fatty acid
- BEHAVIORAL Questionnaire administration
Study Locations (1)
Ohio
- The Ohio State University Medical Center, Comprehensive Breast Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT02150525 record still lists
NCT02150525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 180-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (71% lower).
The record links to 4 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT02150525 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02150525 about?
NCT02150525 is a clinical study titled "Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors". This randomized double-blind clinical trial studied the effect of oral omega-3 fatty acid on atrophic vaginitis in postmenopausal breast cancer survivors (N=52). Omega-3 fatty acid may reduce inflammation and improve vaginal symptoms in postmenopausal breast cancer survivors.
What is the current status of trial NCT02150525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-08. Estimated completion is 2013-01.
What conditions does trial NCT02150525 study?
This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I, Ductal Breast Carcinoma in Situ.
What interventions are being tested in trial NCT02150525?
The interventions under investigation include: placebo (OTHER), omega-3 fatty acid (DIETARY_SUPPLEMENT), Questionnaire administration (BEHAVIORAL).
Who is sponsoring clinical trial NCT02150525?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02150525 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Stage II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02150525's enrollment target sits among peer trials
52 16th of 22 higher than 7 of 22 other Breast Cancer Stage II trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer Stage II trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
RECRUITING · Phase 2
-
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
RECRUITING · Phase 2
-
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
RECRUITING · Phase 2
-
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
RECRUITING · Phase 2
-
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia